ITeos Therapeutics

ITEOS THERAPEUTICS INC

ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.

movers image

FTEL

ITOS

MUFG

SEDG

SKYH

VSAT

Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

Crude Oil 6- logo

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ASND

NCNA

NUVL

Crude Oil Surges Over 1%; Instil Bio Shares Plunge

Movers

Pre-Market Outlook

HYLN

MRNO

MSTR

NVMI

SLDB

UPST

VZLA

iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

ITeos Therapeutics Inc

Health Care

Press Releases

iTeos to Participate in Upcoming Investor Conferences

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress

Earnings

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Economics

iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025

Abeona Therapeutics

Anika Therapeutics

Annexon

aTyr Pharma

Candel Therapeutics

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Cargo Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Design Therapeutics

Emergent BioSolutions

Foghorn Therapeutics

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Humacyte

Immutep Limited - American Depositary Shares

Immutep

Inhibrx Biosciences

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Nuvectis Pharma

Ocugen

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

AVITA Medical

Solid Biosciences

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

XOMA Royalty

Y-mAbs Therapeutics

Wells Fargo

JP Morgan

HC Wainwright & Co.

Wedbush

Comments

ITeos Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga